LLY

728.67

-2.49%↓

JNJ

153.66

+0.1%↑

ABBV

182.32

-1.03%↓

NVO

68.3

+0.57%↑

UNH

305

-5.37%↓

LLY

728.67

-2.49%↓

JNJ

153.66

+0.1%↑

ABBV

182.32

-1.03%↓

NVO

68.3

+0.57%↑

UNH

305

-5.37%↓

LLY

728.67

-2.49%↓

JNJ

153.66

+0.1%↑

ABBV

182.32

-1.03%↓

NVO

68.3

+0.57%↑

UNH

305

-5.37%↓

LLY

728.67

-2.49%↓

JNJ

153.66

+0.1%↑

ABBV

182.32

-1.03%↓

NVO

68.3

+0.57%↑

UNH

305

-5.37%↓

LLY

728.67

-2.49%↓

JNJ

153.66

+0.1%↑

ABBV

182.32

-1.03%↓

NVO

68.3

+0.57%↑

UNH

305

-5.37%↓

Search

Innoviva Inc

Ouvert

SecteurSoins de santé

18.99 1.06

Résumé

Variation du prix de l'action

24h

Actuel

Min

18.61

Max

19.07

Chiffres clés

By Trading Economics

Revenu

-67M

-47M

Ventes

-3.2M

89M

P/E

Moyenne du Secteur

51.694

56.602

BPA

0.26

Marge bénéficiaire

-52.559

Employés

127

EBITDA

17M

36M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+192.86% upside

Dividendes

By Dow Jones

Prochains Résultats

29 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-8.2M

1.2B

Ouverture précédente

17.93

Clôture précédente

18.99

Sentiment de l'Actualité

By Acuity

63%

37%

343 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Innoviva Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mai 2025, 20:54 UTC

Acquisitions, Fusions, Rachats

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mai 2025, 20:50 UTC

Résultats

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mai 2025, 23:48 UTC

Acquisitions, Fusions, Rachats

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mai 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mai 2025, 23:39 UTC

Market Talk

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mai 2025, 23:08 UTC

Market Talk

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mai 2025, 22:45 UTC

Acquisitions, Fusions, Rachats

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mai 2025, 22:44 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mai 2025, 22:20 UTC

Actualités

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q EPS 10c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Sales $972M >JHX

20 mai 2025, 20:52 UTC

Actualités

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mai 2025, 20:52 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2025, 20:52 UTC

Market Talk

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mai 2025, 20:30 UTC

Acquisitions, Fusions, Rachats

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mai 2025, 20:28 UTC

Acquisitions, Fusions, Rachats

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mai 2025, 20:23 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Adj EPS BRL2.29 >XP

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Rev BRL4.345B >XP

20 mai 2025, 20:21 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mai 2025, 20:20 UTC

Actualités

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mai 2025, 20:19 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mai 2025, 20:11 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mai 2025, 20:09 UTC

Résultats

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Comparaison

Variation de prix

Innoviva Inc prévision

Objectif de Prix

By TipRanks

192.86% hausse

Prévisions sur 12 Mois

Moyen 55 USD  192.86%

Haut 55 USD

Bas 55 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

18.57 / 18.75Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

343 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.